Similar articles

• Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.

  Alward WL. Alward WL. Am J Ophthalmol. 2001 Sep;132(3):449-51. doi: 10.1016/s0002-9394(01)01101-1. Am J Ophthalmol. 2001. PMID: 11554384 No abstract available.
• Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.

  Stewart WC, Sharpe ED, Stewart JA, Holmes KT, Latham KE. Stewart WC, et al. Am J Ophthalmol. 2001 Mar;131(3):339-44. doi: 10.1016/s0002-9394(00)00824-2. Am J Ophthalmol. 2001. PMID: 11239866 Clinical Trial.
• Substituting latanoprost (Xalatan) for isopropyl unoprostone (Rescula) in monotherapy and combination therapy.

  Tsukamoto H, Yokoyama T, Okada K, Okada M, Mochizuki H, Mishima HK. Tsukamoto H, et al. Acta Ophthalmol Scand. 2000 Oct;78(5):604-5. doi: 10.1034/j.1600-0420.2000.078005604.x. Acta Ophthalmol Scand. 2000. PMID: 11037926 Free PMC article. Clinical Trial. No abstract available.
• Current status of prostaglandin therapy: latanoprost and unoprostone.

  Susanna R Jr, Chew P, Kitazawa Y. Susanna R Jr, et al. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S97-104. doi: 10.1016/s0039-6257(02)00308-9. Surv Ophthalmol. 2002. PMID: 12204705 Review.
• [Latanoprost topical ophthalmic combinations].

  Călugăru M, Călugăru D. Călugăru M, et al. Oftalmologia. 2004;48(4):18-28. Oftalmologia. 2004. PMID: 15782758 Review. Romanian.